MOUNTAIN VIEW, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. announced today that Andrew L. Busser has been appointed to its Board of Directors. Mr. Busser is currently a Partner, Managing Member and Co-Founder of Symphony Capital LLC. Mr. Busser was nominated to be appointed to the Alexza Board of Directors, pursuant to the terms of Alexza's agreement to acquire the outstanding equity of Symphony Allegro, which was completed on August 26, 2009.
"We are very pleased to welcome Andy to our Board of Directors," said Thomas B. King, President and CEO of Alexza Pharmaceuticals, Inc. "We have been working with Andy since 2006, and look forward to his expanded contributions to Alexza as we move into the next stage of Alexza's development with the commercialization of AZ-004 (Staccato loxapine)."
AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting a New Drug Application submission in early 2010.
AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial. Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at www.alexza.com.
Alexza Pharmaceuticals, Inc.
